MKNK2
MAPK Interacting Serine/Threonine Kinase 2
Gene Information Card
| Symbol | MKNK2 |
|---|---|
| Full Name | MAPK interacting serine/threonine kinase 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 19p13.3 |
| NCBI Gene ID | 2872 ncbi.nlm.nih.gov/gene/2872 |
| Ensembl ID | ENSG00000199832 |
| UniProt ID | Q9HBI1 |
| OMIM ID | 605620 |
| HGNC ID | 7111 |
| Aliases | GPRK7, Mnk2, MKNK2a, MKNK2b |
Description
MKNK2 (MAPK interacting serine/threonine kinase 2) encodes a member of the MAP kinase-interacting serine/threonine kinase family. This kinase is activated by ERK and p38 MAP kinases and phosphorylates eukaryotic initiation factor 4E (eIF4E), thereby regulating translation initiation. MKNK2 is involved in cellular stress responses, proliferation, and survival, and has been implicated in various cancers and neurological disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | Dysregulation of MKNK2 leads to altered eIF4E phosphorylation and aberrant translation of oncogenic mRNAs | COSMIC, ClinVar |
| Neurodevelopmental disorders | Mutations in MKNK2 may affect synaptic plasticity and translation control | OMIM |
| Cancer (various types) | Dysregulation of MKNK2 leads to altered eIF4E phosphorylation, promoting oncogenic translation and tumor growth. | COSMIC; PubMed studies |
| Neurodevelopmental disorders | Rare variants in MKNK2 have been associated with intellectual disability and autism spectrum disorder. | ClinVar; OMIM |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Heart | 8.3 | Low |
| Liver | 4.1 | Low |
| Lung | 6.7 | Low |
| Kidney | 9.2 | Low |
| Testis | 15.8 | Medium |
| Brain | 12.5 | Medium |
| Heart | 8.3 | Low |
| Liver | 4.1 | Low |
| Testis | 15.2 | Medium |
| Skeletal muscle | 6.7 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK293 | 18.2 | Embryonic kidney cells |
| HeLa | 22.5 | Cervical cancer cells |
| A549 | 14.7 | Lung cancer cells |
| MCF7 | 11.3 | Breast cancer cells |
| HEK293 | 18.5 | High expression |
| HeLa | 12.3 | Moderate expression |
| K562 | 9.8 | Moderate expression |
| A549 | 7.2 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1015C>T (p.Arg339Trp) | Missense | 0.02% | Unknown functional impact |
| c.1246G>A (p.Gly416Arg) | Missense | 0.01% | Potential loss of kinase activity |
| c.1015C>T (p.Arg339Trp) | Missense | <0.1% | Unknown functional impact; reported in ClinVar |
| c.1246G>A (p.Glu416Lys) | Missense | <0.1% | Likely benign |
| Amplification | Copy number gain | 1-2% in cancers | Potential gain-of-function in tumors |
Mutation functional classification
Loss of Function (LOF)
Missense mutations in the kinase domain may reduce catalytic activity.
Gain of Function (GOF)
Not well characterized; some variants may increase eIF4E phosphorylation.
Dominant Negative (DN)
Not reported.
Loss of Function (LOF)
No well-characterized loss-of-function mutations reported in major databases.
Gain of Function (GOF)
Amplification or overexpression may lead to increased eIF4E phosphorylation and oncogenic translation.
Dominant Negative (DN)
Not described for MKNK2.
View complete mutation data：
Gene Ontology (GO)
| • protein serine/threonine kinase activity | • ATP binding |
| • MAP kinase activity | • translation initiation factor binding |
| • eIF4E binding | • nucleus |
| • cytoplasm | • regulation of translation |
| • signal transduction | • cell proliferation |
Pathways
• MAPK signaling pathway
• mTOR signaling pathway
• eIF4E-mediated translation regulation
• ErbB signaling pathway
Protein Summary
MKNK2 encodes a serine/threonine kinase that phosphorylates eIF4E, a key regulator of cap-dependent translation. The protein contains an N-terminal kinase domain and a C-terminal MAPK-binding domain. Alternative splicing generates two isoforms (Mnk2a and Mnk2b) with distinct regulatory properties. MKNK2 is widely expressed, with highest levels in brain and testis, and is implicated in cancer cell growth and survival.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| MKNK2 Knockout HEK293 Cell Line | EDJ-KQ907 | Human | 2872 | Details Get a Quote |
| MKNK2 Knockout A-549 Cell Line | EDJ-KQ21094 | Human | 2872 | Details Get a Quote |
| MKNK2 Knockout HCT 116 Cell Line | EDJ-KQ21096 | Human | 2872 | Details Get a Quote |
| MKNK2 Knockout HeLa Cell Line | EDJ-KQ21097 | Human | 2872 | Details Get a Quote |
| MKNK1 and MKNK2 Knockout HeLa Cell Line | EDC90237 | Human | 8569 and 2872 | Details Get a Quote |
Displaying Records 1 To 5 Of 5 Records
